Phase I study of afatinib and radiotherapy (RT) with or without temozolomide (TMZ) in newly diagnosed glioblastoma (GB).

被引：0
|
作者：
Saran, Frank
Welsh, Liam
James, Allan
McBain, Catherine
Gattamaneni, Rao
Jefferies, Sarah
Harris, Fiona
Cseh, Agnieszka
Pemberton, Karine
Schaible, Jennifer
Bender, Shaun
Brada, Michael
机构：
[1] Royal Marsden NHS Fdn Trust, London, England
[2] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[3] Christie NHS Fdn Trust, Manchester, Lancs, England
[4] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England
[5] Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria
[6] Boehringer Ingelheim Ltd, Bracknell, Berks, England
[7] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[8] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[9] Clatterbridge Canc Ctr NHS Fdn Trust, Bebington, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.2036
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2036
引用
收藏
页数：2
相关论文
共 50 条
  • [31] PHASE I STUDY OF IBRUTINIB WITH RADIATION AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Ahluwalia, Manmeet
    Patel, Neha
    Khosla, Atulya
    Rauf, Yasmeen
    Stevens, Glen
    Murphy, Erin
    Chao, Samuel
    Yu, Jennifer
    Suh, John
    Peereboom, David
    NEURO-ONCOLOGY, 2022, 24 : 60 - 60
  • [32] PHASE I STUDY OF IBRUTINIB WITH RADIATION AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
    Rauf, Yasmeen
    Peereboom, David
    Fallah, Jaleh
    Schilero, Cathy
    Lackner, Pamela
    Stevens, Glen
    Ahluwalia, Manmeet
    NEURO-ONCOLOGY, 2020, 22 : 37 - 37
  • [33] Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma
    Omuro, Antonio
    Beal, Kathryn
    Gutin, Philip
    Karimi, Sasan
    Correa, Denise D.
    Kaley, Thomas J.
    DeAngelis, Lisa M.
    Chan, Timothy A.
    Gavrilovic, Igor T.
    Nolan, Craig
    Hormigo, Adilia
    Lassman, Andrew B.
    Mellinghoff, Ingo
    Grommes, Christian
    Reiner, Anne S.
    Panageas, Katherine S.
    Baser, Raymond E.
    Tabar, Viviane
    Pentsova, Elena
    Sanchez, Juan
    Barradas-Panchal, Renata
    Zhang, Jianan
    Faivre, Geraldine
    Brennan, Cameron W.
    Abrey, Lauren E.
    Huse, Jason T.
    CLINICAL CANCER RESEARCH, 2014, 20 (19) : 5023 - 5031
  • [34] PHASE I STUDY OF VANDETANIB WITH RADIATION THERAPY AND TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA
    Drappatz, Jan
    Norden, Andrew
    Wong, Eric T.
    Doherty, Lisa
    LaFrankie, Debra
    Ciampa, Abigail
    Kesari, Santosh
    Sceppa, Christine
    Gerard, Mary
    Phan, Phuong
    Lassman, Andrew B.
    Schiff, David
    Batchelor, Tracy
    Ligon, Keith L.
    Young, Geoffrey
    Muzikansky, Alona
    Weiss, Stephanie
    Wen, Patrick Y.
    NEURO-ONCOLOGY, 2009, 11 (05) : 634 - 634
  • [35] Phase I study of vandetanib with radiation therapy and temozolomide for newly diagnosed glioblastoma
    Drappatz, J.
    Norden, A. D.
    Wong, E. T.
    Lassman, A. B.
    Doherty, L.
    LaFrankie, D.
    Gerard, M.
    Phan, P.
    Schiff, D.
    Wen, P. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme
    Athanassiou, H
    Synodinou, M
    Maragoudakis, E
    Paraskevaidis, M
    Verigos, C
    Misailidou, D
    Antonadou, D
    Saris, G
    Beroukas, K
    Karageorgis, P
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) : 2372 - 2377
  • [37] THE EFFECT OF TIMING OF RADIOTHERAPY (RT) IN PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) RECEIVING TEMOZOLOMIDE (TMZ): AN ANALYSIS BASED ON THE UCSF EXPERIENCE
    Han, S. J.
    Rutledge, W. C.
    Molinaro, A. M.
    Chang, S.
    Clarke, J. L.
    Prados, M. D.
    Berger, M. S.
    Butowski, N. A.
    NEURO-ONCOLOGY, 2014, 16
  • [38] THE EFFECT OF DELAYING RADIOTHERAPY (RT) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) RECEIVING TEMOZOLOMIDE (TMZ): A SECONDARY ANALYSIS BASED ON THE UCSF EXPERIENCE
    Butowski, Nicholas A.
    Polley, Mei-Yin C.
    Lamborn, Kathleen L.
    Chang, Susan
    Prados, Michael
    Clarke, Jennifer L.
    Huang, Kim
    Sneed, Patricia
    NEURO-ONCOLOGY, 2009, 11 (05) : 665 - 665
  • [39] NCCTG phase I trial of temsirolimus (CCI-779) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients
    Sarkaria, J. N.
    Galanis, E.
    Wu, W.
    Giannini, C.
    Jaeckle, K. A.
    Doyle, L.
    Uhm, J.
    Brown, P.
    Dietz, A. B.
    Buckner, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143
    Omuro, Antonio
    Reardon, David A.
    Sampson, John H.
    Baehring, Joachim
    Sahebjam, Solmaz
    Cloughesy, Timothy F.
    Chalamandaris, Alexandros-Georgios
    Potter, Von
    Butowski, Nicholas
    Lim, Michael
    NEURO-ONCOLOGY ADVANCES, 2022, 4 (01)
12345